Century Therapeutics, Inc. (IPSC)

Name: Century Therapeutics, Inc. (IPSC) annual fundamentals
Creator: TickerFacts
License: https://creativecommons.org/publicdomain/zero/1.0/

Build a valuation ↗↓ Download CSV

CIK 0001850119 · Nasdaq · Biological Products, (No Diagnostic Substances)

Sector Manufacturing
Incorporated DE
Fiscal year ends Dec 31

For the year ended 2025-12-31, Century Therapeutics, Inc. reported revenue of $109.16M.

Key ratios (year ended 2025-12-31)

-15.8%

Operating margin

-8.8%

Net margin

-6.0%

Return on year-end equity

n/m

Revenue growth (YoY)

Beyond the statements

Follow the company.

Explore new filings, reported insider transactions and company relationships.

Open company research ↗

Latest selected filing: Form 8-K (current report) · 2026-10-02

Annual financials

Annual flows and balances are grouped by their actual period end. Select a figure to open its SEC filing. n/a means a matching observation is unavailable. Free cash flow is operating cash flow minus capital expenditures, and EBITDA is operating income plus depreciation and amortization, for the same period, computed by TickerFacts.

The first column covers the twelve months to 2026-06-30 from the latest quarterly report: flows are the last fiscal year plus this year to date minus the same months a year earlier, and balances are as of that date. Per-share figures are annual only.

Period ended	TTM to 2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31
Revenue	n/a	$109.16M	$6.59M	$2.23M	$5.20M	n/a	n/a
R&D Expense	$78.93M	$95.67M	$107.24M	$92.71M	$97.17M	$75.65M	$39.68M
Operating Income	-$116.99M	-$17.27M	-$138.14M	-$146.55M	-$133.83M	-$94.88M	-$53.90M
Net Income	-$109.79M	-$9.58M	-$126.57M	-$136.67M	-$130.93M	-$95.82M	-$53.58M
EPS (Diluted)	n/a	-$0.14	-$1.61	-$2.30	-$2.96	-$2.96	-$7.16
Total Assets	$287.01M	$223.70M	$353.22M	$360.69M	$486.54M	$437.38M	$106.78M
Total Liabilities	$54.66M	$64.77M	$191.85M	$175.94M	$183.81M	$41.14M	$33.43M
Long-Term Debt	n/a	n/a	n/a	n/a	$10.39M	$10.39M	n/a
Shareholders' Equity	$232.34M	$158.94M	$161.36M	$184.75M	$302.74M	$396.24M	-$106.41M
Cash & Equivalents	$49.64M	$61.85M	$58.44M	$47.32M	$84.27M	$56.45M	$27.21M
Operating Cash Flow	-$86.76M	-$103.88M	-$110.14M	-$88.35M	$14.05M	-$89.00M	-$41.27M
Capital Expenditures	$1.33M	$848.0K	$154.0K	$13.74M	$30.60M	$44.97M	$9.82M
Free Cash Flow	-$88.09M	-$104.72M	-$110.29M	-$102.08M	-$16.55M	-$133.97M	-$51.09M
Shares Outstanding	180.55M	87.52M	85.84M	60.34M	55.01M	58.47M	7.48M
Weighted Average Diluted Shares	n/a	86.56M	78.65M	59.31M	32.39M	32.39M	7.48M
EPS (Basic)	n/a	-$0.14	-$1.61	-$2.30	-$2.27	-$2.96	-$7.16

Price chart

Chart and quotes by TradingView. Exchange coverage and delays vary.

Open chart on TradingView